Medical Technology is now available on all devices. Read it for free here.
Consumer technology has advanced rapidly over the past few decades, with modern devices and applications becoming central tools in our daily lives. But for patients that rely on medical implants to maintain their health, next-generation consumer technology is not always a welcome addition – in fact, it can be seriously harmful.
The issue gained mainstream attention earlier this year when technology giant Apple released a list of consumer tech that it advised should be kept a safe distance away from implanted medical devices, such as pacemakers and defibrillators to prevent potential magnetic interference.
But is it realistic to expect patients to avoid such widely used items, or should medical manufacturers be looking for solutions to prevent such events from happening? In this issue, we take a look at the issue of magnetic interference and ask how the medical and tech industry could address the problem.
Also, with artificial intelligence continuing to make waves in healthcare, we ask if regulators are prepared to keep pace with rapid innovation in the sector, track the rise and fall of Theranos founder Elizabeth Holmes, and examine if a test for chronic fatigue syndrome could be on the horizon.
All this, plus the latest insight and analysis from GlobalData.
In this issue
When opposites attract: the problematic pull of pacemakers Apple has released a list of devices that patients should keep away from pacemakers to prevent the magnets housed inside of them from interfering with the vital performance of the medical device. As the market for consumer devices that utilise magnets grows, Chloe Kent examines how manufacturers might address the issue. Read the article here.
Can regulators keep up with AI in healthcare? As more and more AI and data-driven healthcare products are brought to market, how can regulators keep pace with this rapidly evolving technology and ensure it always benefits patients? Abi Millar finds out. Read the article here.
Elizabeth Holmes on trial: the case against the Theranos founder Theranos founder Elizabeth Holmes is facing up to 20 years in prison on multiple charges of conspiracy and fraud. Chloe Kent explores the impact that the device scandal has had on female-led companies, and what the future holds for the controversial former chief executive. Read the article here.
Will there ever be a test for chronic fatigue syndrome? Chronic fatigue syndrome is notoriously difficult to diagnose and treat. But, with long Covid shining a light on similar symptoms, Chloe Kent asks if a test for the condition could become a reality for patients. Read the article here.
Inside the UK’s PCR price problem Despite being a key part of the UK’s international travel requirements not all PCR tests are created equal, and more than 80 companies have been warned after displaying lower prices on the government’s website than are available at checkout. Chloe Kent investigates. Read the article here.
Simulating the Covid-19 vaccine rollout The Certara Vaccine Simulator accurately predicted an eight-week optimal timing interval between Covid-19 vaccine doses. Chloe Kent speaks to Certara QSP senior vice-president Piet van der Graaf about how the simulator was developed and how it may be used in the future. Read the article here.
Next issue preview
Two decades after scientists first released the draft sequence of the human genome, an international team of genetics research announced that they had successfully mapped 100% of the human genome – identifying more than 100 new genes and millions of genetic variations between humans, some of which could play a role in disease.
While this discovery may be ground-breaking for the genomics sector, switching to a full model of the human genome could prove to be a challenge for many clinical labs, which will have to adjust to this new map of human physiology. To find out more, we speak to genomics experts to find out what clinical labs can do to keep up with this research.
Also in the next issue of Medical Technology, we take a trip to Africa to examine the continent’s potential as a clinical trial powerhouse. Despite being home to some of the world’s most diverse and densely populated nations, Africa currently contributes to less than 2% of the total number of clinical trials. Could more be done to utilise these seemingly ideal research conditions?